Cohort1: Anti-VEGF Simultaneous Regimen
|
Administration route |
None |
Pts |
38 |
Age |
Adult, Older_Adult |
Adverse reactions |
2/63(All-cause mortality); 19/63(Blood and lymphatic system disorders; Cardiac disorders; Endocrine disorders; Eye disorders; Gastrointestinal disorders; General disorders; Hepatobiliary disorders; Immune system disorders; Infections and infestations; Injury, poisoning and procedural complications; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Nervous system disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders) |
|
Cohort2: Anti-VEGF Pre-Treatment Regimen
|
Administration route |
None |
Age |
Adult, Older_Adult |
Adverse reactions |
2/38(All-cause mortality); 8/38(Cardiac disorders; Gastrointestinal disorders; Hepatobiliary disorders; Infections and infestations; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Respiratory, thoracic and mediastinal disorders; Vascular disorders) |
|